Arachidonylcyclopropylamide (ACPA)

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Arachidonylcyclopropylamide (ACPA)
• 英文别名: (5E,8E,11E,14E)-N-cyclopropylicosa-5,8,11,14-tetraenamide
• 化学式: C₂₃H₃₇NO
• 分子量: 343.5
• InChiKey: GLGAUBPACOBAMV-CGRWFSSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  25
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Methods, compositions and compound assays for inhibiting amyloid-beta protein production
  申请人：Merchiers Gerard Pascal

  公开号：US20050287565A1

  公开（公告）日：2005-12-29

  A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a GPCR polypeptide, or fragment thereof, and measuring a compound-GPCR property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including second messenger and/or amyloid beta peptide levels. Therapeutic methods, and pharmaceutical compositions including effective amyloid-beta precursor processing-inhibiting amounts of GPCR expression inhibitors, are useful for treating conditions involving cognitive impairment such as Alzheimers Disease.

  一种鉴定抑制细胞中淀粉样β前体蛋白加工的化合物的方法，包括将测试化合物与 GPCR 多肽或其片段接触，并测量与淀粉样β肽的产生有关的化合物-GPCR 特性。该方法的细胞测定测量指标包括第二信使和/或淀粉样 beta 肽水平。治疗方法和药物组合物包括有效的淀粉样β前体加工抑制量的GPCR表达抑制剂，可用于治疗涉及认知障碍的疾病，如阿尔茨海默病。
• USE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE
  申请人：AstraZeneca AB

  公开号：EP1453497A1

  公开（公告）日：2004-09-08
• Use for the treatment of gastroesophageal reflux disease
  申请人：——

  公开号：US20040266861A1

  公开（公告）日：2004-12-30

  The present invention relates to the use of cannabinoid receptor agonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of cannabinoid receptor agonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation such as regurgitation in infants, lung disease, chronic laryngitis and asthma.
• US7358245B2
  申请人：——

  公开号：US7358245B2

  公开（公告）日：2008-04-15
• [EN] NEW USE FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE<br/>[FR] PROCÉDÉ DE TRAITEMENT DU REFLUX GASTRO-OESOPHAGIEN
  申请人：ASTRAZENECA AB

  公开号：WO2003043619A1

  公开（公告）日：2003-05-30

  The present invention relates to the use of cannabinoid receptor agonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of cannabinoid receptor agonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation such as regurgitation in infants, lung disease, chronic laryngitis and asthma.